Replies to post #17222 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

The interesting subtext is that Lilly's current lead glutamatergic mechanism is via mGluR: wherein their lead compound did not equal Zyprexa's efficacy in Phase II; and their head mGluR guy left and went to Merck.


NeuroInvestment

[Market_Fest4]

Lilly's power over the FDA is the reason they held up CX-717 and ultimately killed it for ADHD.

Don't kid yourself, the FDA is just as bought and paid for as congress is.
MF4